Cargando…

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users

Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jansen, Marleen E., Rigter, Tessel, Fleur, Thom M. C., Souverein, Patrick C., Verschuren, W. M. Monique, Vijverberg, Susanne J., Swen, Jesse J., Rodenburg, Wendy, Cornel, Martina C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957000/ https://www.ncbi.nlm.nih.gov/pubmed/36833383 http://dx.doi.org/10.3390/genes14020456

Ejemplares similares

Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins
por: Dou, Ye, et al.
Publicado: (2015)

Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case–Control Studies
por: Hou, Qingtao, et al.
Publicado: (2015)

Association between SLCO1B1 −521T>C and −388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis
por: Jiang, Jiajia, et al.
Publicado: (2016)

Effects of Soy Isoflavones and Green Tea Extract on Simvastatin Pharmacokinetics and Influence of the SLCO1B1 521T > C Polymorphism
por: Zeng, Weiwei, et al.
Publicado: (2022)

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin
por: Park, Jin-Woo, et al.
Publicado: (2022)

Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity
por: Jansen, Marleen E., et al.
Publicado: (2017)

SLCO1B1 Polymorphisms and Statin-Induced Myopathy
por: Stewart, Alison
Publicado: (2013)

Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide
por: Cornel, Martina C., et al.
Publicado: (2020)

Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective
por: Rigter, Tessel, et al.
Publicado: (2020)

Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 −106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients
por: Shu, Qing, et al.
Publicado: (2021)

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants
por: Lönnberg, K. Ivar, et al.
Publicado: (2023)

Pursuing Public Health Benefit Within National Genomic Initiatives: Learning From Different Policies
por: Onstwedder, Suzanne M., et al.
Publicado: (2022)

Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant
por: Merkel, Melissa, et al.
Publicado: (2021)

Moving somatic gene editing to the clinic: routes to market access and reimbursement in Europe
por: Rigter, Tessel, et al.
Publicado: (2021)

Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long‐term outcomes in women and men
por: Türkmen, Deniz, et al.
Publicado: (2022)

SLCO1B1 Polymorphism is not associated with Risk of Statin-Induced Myalgia/Myopathy in a Czech Population
por: Hubáček, Jaroslav A., et al.
Publicado: (2015)

SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017)

1136. Universal Prophylaxis for Prevention of Invasive Aspergillus in Lung Transplant Recipients
por: Guenette, Alexis, et al.
Publicado: (2018)

Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy
por: Xiao, Yu‐Feng, et al.
Publicado: (2022)

Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations
por: Nagy, Agnes, et al.
Publicado: (2015)

A Cost–Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care
por: Brunette, Charles A., et al.
Publicado: (2021)

Should we test for SLCO1B1 genotype before prescribing statins?—a discussion of clinical trial results
por: Zhou, Yitian, et al.
Publicado: (2022)

A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance
por: Bigossi, Margherita, et al.
Publicado: (2023)

Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
por: Song, Gonjin, et al.
Publicado: (2021)

1136 Surveillance of Acute Flaccid Paralysis (AFP) in the Republic of Korea during 2012-2013
por: Yoon, Young-Sil, et al.
Publicado: (2014)

Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report
por: Dagli-Hernandez, Carolina, et al.
Publicado: (2021)

SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals
por: Prado, Yalena, et al.
Publicado: (2015)

SLCO1B1 c.388A > G variant incidence and the severity of hyperbilirubinemia in Indonesian neonates
por: Amandito, Radhian, et al.
Publicado: (2019)

SLCO4A1-AS1 promotes colorectal tumourigenesis by regulating Cdk2/c-Myc signalling
por: Zhang, Jia, et al.
Publicado: (2022)

Statin Use and Markers of Immunity in the Doetinchem Cohort Study
por: De Jong, Hilda J.I., et al.
Publicado: (2013)

Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
por: Rodrigues, Alice C., et al.
Publicado: (2011)

Stakeholder perspectives on the implementation of genetic carrier screening in a changing landscape
por: Holtkamp, Kim C.A., et al.
Publicado: (2017)

A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy
por: Turongkaravee, Saowalak, et al.
Publicado: (2021)

1136. Antifungal Prescribing Patterns among Hospitalized Children in the United States: Are There Opportunities for Antifungal Stewardship?
por: Eguiguren, Lourdes, et al.
Publicado: (2019)

A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
por: Lehtisalo, Minna, et al.
Publicado: (2022)

Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
por: Aquilante, Christina L, et al.
Publicado: (2008)

Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
por: Vasilyev, Filipp Filippovich, et al.
Publicado: (2016)

Tyrosine phosphorylation of Munc18c on residue 521 abrogates binding to Syntaxin 4
por: Aran, Veronica, et al.
Publicado: (2011)

P1136: INTERIM IMAGING DOES NOT PREDICT CLINICAL EVOLUTION IN FOLLICULAR LYMPHOMA IN A REAL-LIFE CLINICAL SETTING
por: Ramos De Ascanio, V., et al.
Publicado: (2022)

DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
por: Martens, Forike K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_10v64t88kooc06lvbtg3oa2aur